# A Prospective, Single-arm, Phase II Clinical Study of Tislelizumab Combined With Anlotinib and Platinum-based Doublet Perioperative Therapy for Resectable Stage II-IIIB Driver Gene-negative NSCLC

> **NCT06977828** · PHASE2 · NOT_YET_RECRUITING · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 40 (estimated)

## Conditions studied

- NSCLC (Non-small Cell Lung Cancer)
- Neoadjuvant Immunotherapy
- Adjuvant Immunotherapy

## Interventions

- **DRUG:** tislelizumab in combination with anlotinib and platinum-based doublet chemotherapy

## Key facts

- **NCT ID:** NCT06977828
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-07-20
- **Primary completion:** 2027-06-30
- **Final completion:** 2028-12-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06977828

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06977828, "A Prospective, Single-arm, Phase II Clinical Study of Tislelizumab Combined With Anlotinib and Platinum-based Doublet Perioperative Therapy for Resectable Stage II-IIIB Driver Gene-negative NSCLC". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT06977828. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*